Abnormal Involuntary Movements Scale, 7
adherence to treatment
psychological health and, 63
sexual dysfunction and, 105, 108
urinary incontinence and, 129, 133
adrenergic receptors
effects on vital signs, 141, 143
urinary incontinence and, 129
age, 13. See also elderly patients
risk of
cardiovascular disease, 31, 35
clozapine-induced agranulocytosis, 12, 13
diabetes mellitus, 29
agranulocytosis
clozapine, 12
clozapine-induced, 12
definition, 14
first-generation agents, 13
haloperidol, 13
monitoring, 15
olanzapine, 12, 13
phenothiazines, 13
quetiapine, 12
risk factors, 12, 13
risperidone, 12, 13
signs and symptoms, 14
akathisia, 39, 123
aripiprazole, 40
Extrapyramidal Symptom Rating Scale (ESRS), 43-50
haloperidol, 42
monitoring, 43, 127
olanzapine, 41
perphenazine, 42
quetiapine, 41
risperidone, 42
ziprasidone, 42
allergy. See hypersensitivity
altered mental status in neuroleptic malignant syndrome, 59, 61
amisulpride, 4
amoxapine, 4
anesthesia, chlorpromazine potentiates, 3
angioma, spider, 55
anticholinergic
drugs
effects, 18–22
interaction with antimuscarinic, 18, 22
effects
aripiprazole, 18
chlorpromazine, 20
clozapine, 18, 20
first-generation antipsychotics, 22
flupenthixol, 20
fluphenazine, 20
haloperidol, 20
loxapine, 20
medications for comorbidity, 20
methotrimeprazine, 20
monitoring, 22
norclozapine, 18
olanzapine, 19, 20
priapism, 105
quetiapine, 20, 20
risperidone, 20, 20
second-generation antipsychotics, 18–22
thioridazine, 20
ziprasidone, 22
medications, extrapyramidal symptoms, 18, 42
antimuscarinic drugs, interaction with anticholinergic, 18, 22
appetite, 62
antipsychotics and, 62
schizophrenia, 62
aripiprazole, 4
akathisia, 40
anticholinergic effects, 18
cardiac death, sudden, 82
diabetes mellitus, 25
dyskinesia, tardive, 124
extrapyramidal symptoms, 40
hepatic effects, 52
leukopenia, 12
lipids, blood, 32
monitoring schedule, 151
neutropenia, 12
obesity and weight gain, 63
prolactin effects, 75
rabbit syndrome, 40
risk of morbidity, 5
sedation, 91
seizures, 98
sexual dysfunction, 105
sialorrhea, 113
skin reactions, 118
sleep disturbances, 91
thrombocytopenia, 12
urinary incontinence, 130
vital signs, 144
atypical antipsychotics. See second-generation antipsychotics
Arizona Sexual Experiences Scale, 106, 108
arousal, chlorpromazine diminishes, 3
assessment of physical health, 6, 7, 175
autonomic dysfunction in neuroleptic malignant syndrome, 59, 61
benztropine
chlorpromazine combined with, 42
haloperidol combined with, 42
bioavailability, CNS, factor in drug effects, 18
bipolar
depression, sleep disturbance with antipsychotics, 92
disorder
antipsychotic-induced sialorrhea, 113
cardiovascular disease, 31, 175
mania, risk of extrapyramidal symptoms, 40
blood
components in blood dyscrasias, 13–14
dyscrasias
antipsychotic-induced, 12–16
monitoring, 13–15, 14, 15
pressure. See also hypertension, hypotension, vital signs
risk for cardiovascular disease, 36
tests, neuroleptic malignant syndrome, 59
body mass index, 62
chart, 66
disease risk and, 63, 67
formulae, 67
normal values, 63
useful websites, 67
bowel obstruction, anticholinergic effect, 18
bradycardia, paradoxical, anticholinergic effect, 18
bradykinesia, 39
Extrapyramidal Symptom Rating Scale (ESRS), 43–50
monitoring, 43
butyrophenones, blood lipids, 33
cancer, breast and prolactinoma, 74
cardiac
death, sudden, 80–7, 141
aripiprazole, 82
chlorpromazine, 84
clozapine, 82
first-generation antipsychotics, 84
haloperidol, 84
monitoring, 85–7
olanzapine, 83
paliperidone, 83
perphenazine, 84
phenothiazines, 141
pimozide, 84
quetiapine, 83
risperidone, 83
sertindole, 81
thioridazine, 84
thiothixene, 85
ziprasidone, 84
effects, 80–7, 141
clozapine, 82, 144
monitoring, 85–7, 86
cardiometabolic risk, monitoring, 7
cardiomyopathy 82, 83, 144
cardiovascular
disease
bipolar disorder, 31
dyslipidemia, 31–3
muscarinic blockade and, 19
risk factors, 32–3, 33
schizophrenia, 31
effects
risperidone, 145
vital signs and, 141–7
care, quality of, in mental illness, 5
improving, 8, 175
cataracts, 69–70
clozapine, 70
clozapine, 69
monitoring, 72
phenothiazines, 70
prochlorperazine, 70
quetiapine, 70
schizophrenia, 69, 70
screening, 72
thioridazine, 70
Changes in Sexual Functioning Questionnaire, 107, 108, 108
clozapine (cont.)
prolactin effects, 75
rabbit syndrome, 41
retinopathy, pigmented, 72
risk of morbidity, 5
sedation, 91
sexual dysfunction, 105
sialorrhea, 41, 113
skin reactions, 118
thrombocytopenia, 12
thrombocytosis, 12
thromboembolism, 136
urinary incontinence, 130
vital signs, 144, 146, 153
cognitive difficulties
anticholinergic effect, 18
muscarinic blockade and, 19
communication, user-provider, in monitoring, 8
comorbidity
drugs for, interact with anticholinergics, 20
effects of drugs and
anticholinergic, 18, 21
cardiac, 82
risk for cardiovascular disease, 33
complications
blood dyscrasias, 12
diabetes mellitus, 24
weight gain, 62, 63
confusion, anticholinergic effect, 18
constipation
anticholinergic effect, 18
clozapine, 18
quetiapine, 20
muscarinic blockade and, 19
conventional antipsychotics. See first-generation antipsychotics
creatine kinase, in neuroleptic malignant syndrome, 59, 61
delirium, anticholinergic effect, 18
olanzapine, 19
dementia, olanzapine-induced delirium, 19
depression
bipolar, sleep disturbance with antipsychotics, 92
risk of extrapyramidal symptoms and, 40
diabetes mellitus, 24–9
aripiprazole, 25
as risk factor
cardiovascular disease, 33
cataracts, 69
chlorpromazine, 27
clozapine, 25
diagnosis, 27, 29
first-generation antipsychotics, 26
haloperidol, 27
monitoring, 28, 29
glycemic control, 27
tools and websites, 29
olanzapine, 25
paliperidone, 25
perphenazine, 27
quetiapine, 26
risk factors, 29
risperidone, 26
schizophrenia and, 24, 25
second-generation antipsychotics and, 24, 25–6
ziprasidone, 26
dizziness, Extrapyramidal Symptom Rating Scale (ESRS), 43–50
dopamine
D₁ agonists, aripiprazole and, 75
D₂ antagonists
switching from to aripiprazole, 75
vital signs, 145
prolactin release and, 74
receptors
agonists, and aripiprazole, 75
antagonists and neuroleptic malignant syndrome, 59
anticholinergic effects and, 22
blockade, and hyperprolactinemia, 74
blockade, and sexual dysfunction and, 104, 106
blockade, and tiredness, 90
D₂ antagonists and extrapyramidal symptoms, 42
D₂ antagonists and neuroleptic malignant syndrome, 59
D₂ antagonists, and sialorrhea, 112
D₂ blockade, 3, 4
dyskinesia, tardive, 123
extrapyramidal symptoms and potency, 40, 42
potency and weight gain, 66
urinary incontinence and, 129
drooling, 41. See also sialorrhea
bradykinesia, 39
clozapine, 41
monitoring, 114
dry mouth
anticholinergic effect, 18
anticholinergic effect, quetiapine, 20
muscarinic blockade and, 19
dyskinesia, 123–7
clozapine, 124
<table>
<thead>
<tr>
<th>Extrapyramidal Symptom Rating Scale (ESRS), 43–50, 127</th>
</tr>
</thead>
<tbody>
<tr>
<td>monitoring, 126, 127</td>
</tr>
<tr>
<td>schizophrenia, 123</td>
</tr>
<tr>
<td>screening for, 175</td>
</tr>
<tr>
<td>signs and symptoms, 125</td>
</tr>
<tr>
<td>tardive, 123–7</td>
</tr>
<tr>
<td>aripiprazole, 124</td>
</tr>
<tr>
<td>haloperidol, 125</td>
</tr>
<tr>
<td>olanzapine, 124</td>
</tr>
<tr>
<td>paliperidone, 124</td>
</tr>
<tr>
<td>perphenazine, 125</td>
</tr>
<tr>
<td>quetiapine, 124</td>
</tr>
<tr>
<td>risperidone, 125</td>
</tr>
<tr>
<td>ziprasidone, 125</td>
</tr>
<tr>
<td>eating behaviors, 62</td>
</tr>
<tr>
<td>education, patient/caregiver, 8</td>
</tr>
<tr>
<td>elderly patients, anticholinergic medications and, 18, 21</td>
</tr>
<tr>
<td>electrocardiogram (ECG), 80</td>
</tr>
<tr>
<td>antipsychotic-induced effects on, 82, 85–7. See also cardiac death</td>
</tr>
<tr>
<td>monitoring, 85–7, 86</td>
</tr>
<tr>
<td>normal values, 85</td>
</tr>
<tr>
<td>embolism. See thromboembolism</td>
</tr>
<tr>
<td>enuresis. See under incontinence</td>
</tr>
<tr>
<td>enzymes, hepatic, 52, 56. See also hepatic effects</td>
</tr>
<tr>
<td>eosinophilia, clozapine and, 12</td>
</tr>
<tr>
<td>epilepsy, 98. See also seizures</td>
</tr>
<tr>
<td>schizophrenia and, 98</td>
</tr>
<tr>
<td>erythema, palmar, liver disease, 55</td>
</tr>
<tr>
<td>excoriations, liver disease, 55</td>
</tr>
<tr>
<td>Extrapyramidal Symptom Rating Scale (ESRS), 7, 43, 43–50, 127</td>
</tr>
<tr>
<td>extrapyramidal symptoms (EPS), 40</td>
</tr>
<tr>
<td>antipsychotic-induced, anticholinergics treat, 18, 20, 21, 22, 42</td>
</tr>
<tr>
<td>aripiprazole, 40</td>
</tr>
<tr>
<td>chlorpromazine, 40, 42</td>
</tr>
<tr>
<td>clozapine, 40, 41</td>
</tr>
<tr>
<td>D₂ antagonists, 42</td>
</tr>
<tr>
<td>Extrapyramidal Symptom Rating Scale (ESRS), 43, 43–50</td>
</tr>
<tr>
<td>haloperidol, 40, 42</td>
</tr>
<tr>
<td>liability of antipsychotic drugs, 40</td>
</tr>
<tr>
<td>monitoring, 43</td>
</tr>
<tr>
<td>monitoring schedule, 44</td>
</tr>
</tbody>
</table>

**Note:** The index entries are organized to reflect the structure and content of the text, capturing key terms and concepts related to antipsychotics and their side effects. Each entry is linked to relevant sections of the book, facilitating quick access to detailed information on the topic.
<table>
<thead>
<tr>
<th>health</th>
<th>physical</th>
</tr>
</thead>
<tbody>
<tr>
<td>of mental health patients, 6–8</td>
<td>weight gain and, 62</td>
</tr>
<tr>
<td>psychological, weight gain undermines, 63</td>
<td></td>
</tr>
</tbody>
</table>

| heart rate, 141. See also vital signs |
| variability, 142 |
| schizophrenia, 142 |

| hematological |
| effects, 12–16 |
| monitoring, 13, 15 |
| parameters |
| blood dyscrasias, 13 |
| clozapine, 14 |

| hepatic |
| effects, 52–5 |
| aripiprazole, 52 |
| chlorpromazine, 55 |
| clozapine, 52 |
| haloperidol, 55 |
| monitoring, 53, 55, 56 |
| olanzapine, 53 |
| paliperidone, 54 |
| phenothiazines, 55 |
| quetiapine, 54 |
| risperidone, 54 |
| ziprasidone, 55 |
| enzymes, 52 |
| monitoring, 56 |
| function test, normal values, 53 |

| hyperlipidemia, 31. See also dyslipidemia, lipids, triglycerides |
| hyperprolactinemia, 74, 75. See also prolactin effects |
| monitoring clinical effects, 76 |
| hypersensitivity, 118–20 |
| clozapine, 119 |
| monitoring, 120, 121 |
| olanzapine, 119 |
| hypertension, 143 |
| as risk factor for cataracts, 69 |
| hypogonadism, 74 |
| hypotension, 142 |
| first-generation antipsychotics, 143 |
| hypothermia, anticholinergic effect, 18 |
icterus, liver disease, 55
ileus, paralytic
anticholinergic effect, 18
clozapine, 18
muscarinic blockade and, 19
incontinence
fetal, clozapine and, 130
muscarinic blockade and, 19
urinary, 129–33
aripiprazole, 130
chlorpromazine, 131
clozapine, 130
flupenthixol, 131
fluphenazine, 131
haloperidol, 131
monitoring, 132, 133
olanzapine, 130
paliperidone, 130
pimozide, 131
quetiapine, 130
risperidone, 130
schizoaffective disorders, 130
schizophrenia, 130
thioridazine, 131
ziprasidone, 131
indifference, chlorpromazine produces, 3
insulin, antipsychotics and, 24
integration in multidisciplinary care, 7
interactions, drug
anticholinergic–antimuscarinic, 18, 22
anticholinergic–comorbidly
medication, 20
cytochrome P450, 102
seizure risk and, 98, 102
involuntary movements, Extrapyramidal Symptom Rating Scale (ESRS), 43–50
itching, hepatic symptom, 55
ketoconazole, 83
kidney disease, as risk factor, cardiovascular disease, 33
leukemia, clozapine, 12
leukocytosis
clozapine, 12
haloperidol, 13
loxapine, 13
molindone, 13
thiothixene, 13
leukopenia, 12
aripiprazole, 12
definition, 14
haloperidol, 13
loxapine, 13
molindone, 13
phenothiazines, 13
quetiapine, 13
risperidone, 13
thiothixene, 13
ziprasidone, 13
liability
extrapyramidal symptoms, of antipsychotics, 40, 40
weight gain, 62
first-generation antipsychotics, 66
life expectancy, schizophrenia, 141
lips, blood. See also dyslipidemia, hyperlipidemia, triglycerides
aripiprazole, 32
butyrophenones, 33
clozapine, 32
monitoring, 33, 34
olanzapine, 32
paliperidone, 32
phenothiazines, 33, 34
quetiapine, 32
risk for cardiovascular disease, 35, 37
useful websites, 33
risperidone, 32
ziprasidone, 33
liver
damage. See hepatic effects
enzymes, 52
monitoring, 56
function tests, normal values, 53
locomotion, chlorpromazine diminishes, 3
loxapine, 4
anticholinergic effects, 20
leukocytosis, 13
leukopenia, 13
sedation, 93
skin reactions, 120
sleep disturbances, 93
lupus-like syndrome, clozapine and, 12
management, physical health, 6
management, physical health in mental health patients, 8
memory difficulties
anticholinergic effect, 18
olanzapine, 89
menstrual irregularity, hyperprolactinemia and, 74, 75, 76, 78
mesoridazine, sedation, 93
metabolic disorders
diabetes mellitus, 24–9
risk
monitoring, 7
schizophrenia, 24
metabolic syndrome, 31
methotrimeprazine
anticholinergic effects, 20
monitoring schedule, 158
sedation, 93
micturition disturbances. See also under incontinence
anticholinergic effects, olanzapine and, 19
olanzapine, 130
risperidone, 130
molindone
leukocytosis, 13
leukopenia, 13
monitoring schedule, 159
sedation, 95
monitoring
agranulocytosis, 15
akathisia, 127
anticholinergic effects, 21, 22
antipsychotic-induced obesity and weight gain, 65
antipsychotic-induced ocular changes, 71
antipsychotic-induced prolactin effects, 77
blood dyscrasias, 13–15, 15
blood in clozapine-induced agranulocytosis, 12, 16
blood lipids, 33, 34
cardiac effects, 85–7, 86
cataracts, 72
charts, change needed, 6
current, of patients taking antipsychotics,
7–8, 175
diabetes mellitus, 28, 29
dyskinesia, 126, 127
dystonia, tardive, 127
ECG effects, 86
extrapyramidal symptoms, 43, 43, 44
General Antipsychotic Monitoring Form
description, 175
FAQs, 176
guide for using, 177
Year 1, 180
Year 2 onwards, 182
hematological effects, 13, 15
hepatic effects, 53, 55, 56
hyperprolactinemia, clinical effects, 76
hypersensitivity, 120, 121
individual antipsychotics, 149
neuroleptic malignant syndrome, 60, 61
obesity and weight gain, 67
patient/caregiver role, 8
physical health in mental health patients, 6–8, 175
prolactin, 76
schedule
anticholinergic effects, 21
antipsychotic-induced agranulocytosis and other blood
dyscrasias, 15
antipsychotic-induced dyslipidemia, 34
antipsychotic-induced obesity and weight gain, 65
antipsychotic-induced ocular changes, 71
antipsychotic-induced prolactin effects, 77
cardiac effects, 86
clozapine, 153
dyskinesia, 126
ECG effects, 86
euprimary symptoms, 44
flupenthixol, 154
fluphenazine, 155
haloperidol, 156
hepatic effects, 56
hypersensitivity, 121
loxapine, 157
methotrimeprazine, 158
molindone, 159
neuroleptic malignant syndrome, 60
new-onset diabetes mellitus, 28
olanzapine, 160
paliperidone, 161
pericyazine, 162
pimozide, 164
pipotiazine palmitate, 165
quetiapine, 166
risperidone, 167
sedation and sleep disturbances, 94
seizures, 101
sexual dysfunction, 109
sialorrhea, 115
skin reactions, 121
thioridazine, 168
thiothixene, 169
urinary incontinence, 132
venous thromboembolism, 138
vital signs, 146
ziprasidone, 171
zuclopenthixol, 172
sedation and sleep disturbances, 94, 95
seizures, 101, 102
sexual dysfunction, 108–10, 109
sialorrhea, 114, 115
skin reactions, 120, 121
thromboembolism, 138, 139
tools and websites in diabetes mellitus, 29
urinary incontinence, 132, 133
vision, 72
vital signs, 146, 147
morbidity
diabetes mellitus, 24
risk
independent of drug therapy, 5
quality of care and, 6
schizophrenia, independent of drug therapy, 24
varies with drug, 5
mortality
diabetes mellitus, 24
risk
independent of drug therapy, 5
quality of care and, 6
varies with drug, 5
thromboembolism, 135
movement disorders, monitoring scales, 7
multidisciplinary approach to care, 7
muscarinic receptors
blockade, 18
effects of, 19
sedation and, 89
effects on vital signs, 141
myocarditis 82, 83, 144

nausea, muscarinic blockade and, 19
neuroleptic malignant syndrome (NMS), 39,
59–61, 144
monitoring, 60, 61
neutropenia, 12
aripiprazole, 12
definition, 14
quetiapine, 13
risperidone, 13
thiothixene, 13
ziprasidone, 13
norclozapine, anticholinergic effects, 18
nutrition, muscarinic blockade and, 19
obesity and weight gain, 62–3
aripiprazole, 63
BMI normal values, 63
chlorpromazine, 66
clozapine, 63
haloperidol, 66
monitoring, 65, 67
olanzapine, 64
paliperidone, 64
quetiapine, 64
risperidone, 64
schizophrenia and, 24, 62
thioridazine, 66
ziprasidone, 64
ocular effects, 69–72. See also cataracts, eye, oculogyric crisis,
retinopathy, vision
monitoring, 71, 72
oculogyric crisis
dyskinesia, tardive, 124
Extrapyramidal Symptom Rating Scale (ESRS), 44–50
paliperidone, 41
ziprasidone, 42
olanzapine, 4
agranulocytosis, 12, 13
akathisia, 41
anticholinergic effects, 19, 20
blood lipids, 32
cardiac death, sudden, 83
diabetes mellitus, 25
dyskinesia, tardive, 124
extrapyramidal symptoms, 40, 41
hepatic effects, 53
hypersensitivity, 119
insulin and, 24
leukopenia, 13
memory, 89
monitoring schedule, 160
neutropenia, 13
obesity and weight gain, 64
parkinsonism, 41
prolactin effects, 75
rabbit syndrome, 41
risk of morbidity, 5
sedation, 92
seizures, 99
sexual dysfunction, 106
sialorrhea, 114
skin reactions, 119
sleep disturbances, 92
olanzapine (cont.)
thrombocytopenia, 13
thromboembolism, 136
tremor, 41
urinary incontinence, 130
vital signs, 144
oral disorders. See also rabbit syndrome
muscarinic blockade and, 19
osteoporosis and prolactinoma, 74
outcome, second-generation vs. first-generation drugs, 6

paliperidone, 4
anticholinergic effects, 20
blood lipids, 32
cardiac death, sudden, 83
diabetes mellitus, 25
dyskinesia, tardive, 124
extrapyramidal symptoms, 40, 41
hepatic effects, 54
monitoring schedule, 161
obesity and weight gain, 64
otulergic crisis, 41
prolactin effects, 75
sedation, 92
seizures, 99
sexual dysfunction, 106
sialorrhrea, 114
skin reactions, 119
sleep disturbances, 92
thromboembolism, 136
urinary incontinence, 130
vital signs, 145
parkinsonian symptoms, 39
parkinsonism
antipsychotic-induced monitoring, 21
sialorrhrea, 112
Extrapyramidal Symptom Rating Scale (ESRS), 43–50
haloperidol, 42
olanzapine, 41
perphenazine, 42
quetiapine, 41
risperidone, 42
ziprasidone, 42
paroxetine, 83
pericyazine monitoring schedule, 162
perphenazine
akathisia, 42
cardiac death, sudden, 84

diabetes mellitus, 27
dyskinesia, tardive, 125
extrapyramidal symptoms, 40, 42
monitoring schedule, 163
parkinsonism, 42
sleep disturbances, 95
phenothiazines
agranulocytosis, 13
blood dyscrasias, 13
blood lipids, 33, 34
cataracts, 70
eye observation of effects, 3
hepatic effects, 55
leukopenia, 13
risk of morbidity, 5
seizures, 100
sexual dysfunction, 107
sudden cardiac death, 141
physical health
of mental health patients, 12–16
weight gain and, 62
pimozide
cardiac death, sudden, 84
monitoring schedule, 164
urinary incontinence, 131
pipotiazine palmitate, monitoring schedule, 165
pneumonia, sialorrhrea and, 112, 113
posture, Extrapyramidal Symptom Rating Scale (ESRS), 43–50
priapism, 104, 110
aripiprazole, 105
chlorpromazine, 107
clozapine, 106
first-generation antipsychotics, 107–8
olanzapine, 106
paliperidone, 106
quetiapine, 106
risperidone, 107
thioridazine, 107
ziprasidone, 451
prochlorperazine, cataracts, 70
prolactin effects, 74–8. See also sexual dysfunction
aripiprazole, 75
clozapine, 75
first-generation antipsychotics, 76
haloperidol, 76
monitoring, 76, 77
olanzapine, 75
Index

palliperidone, 75
quetiapine, 76
risperidone, 76
ziprasidone, 76
prolactinomas, 74
promethazine, early observation of effects, 3
psychological health, weight gain undermines, 63
psychosis
anticholinergic effect, 18
history of pharmacological management, 3
urinary incontinence and, 129
questionnaire, Extrapyramidal Symptom Rating
Scale (ESRS), 43–50
quetiapine, 4
agranulocytosis, 12
akathisia, 41
anticholinergic effects, 20, 20
blood lipids, 32
cardiac death, sudden, 83
cataracts, 70
diabetes mellitus, 26
dyskinesia, tardive, 124
extrapyramidal symptoms, 40, 41
hepatic effects, 54
leukopenia, 13
monitoring schedule, 166
neutropenia, 13
obesity and weight gain, 64
parkinsonism, 41
prolactin effects, 76
rabbit syndrome, 41
risk of morbidity, 5
sedation, 92
seizures, 99
sexual dysfunction, 106
salivation, 114
skin reactions, 119
sleep disturbances, 92
urinary incontinence, 130
vital signs, 145
rabbit syndrome, 39
aripiprazole, 40
clozapine, 41
haloperidol, 42
olanzapine, 41
quetiapine, 41
risperidone, 42
receptors
adrenergic
blockade, sedation and, 89
blockade, sexual dysfunction and, 105
effects on vital signs, 141, 143
role in sialorrhea, 112, 113
urinary incontinence and, 130
binding affinities, 142, 145
antipsychotics, 90
muscarinic, 18, 20
dopamine
agonists, and aripiprazole, 75
antagonists and neuroleptic malignant syndrome, 59
anticholinergic effects and, 22
blockade, and hyperprolactinemia, 74
blockade, and sexual dysfunction and, 104, 106
blockade, and tiredness, 90
D_2 antagonists and extrapyramidal symptoms, 42
D_2 antagonists and neuroleptic malignant syndrome, 59
D_2 antagonists, and sialorrhea, 112
D_2 blockade, 3, 4
dyskinesia, tardive, 123
extrapyramidal symptoms and potency, 40, 42
potency and weight gain, 66
urinary incontinence and, 130
histamine
activity at and weight gain, 62
blockade, and sedation, 92
blockade, and sexual dysfunction and, 104
blockade, sedation and, 89
muscarinic
blockade, 18
blockade, effects of, 19
blockade, sedation and, 89
effects on vital signs, 141
role in sialorrhea, 112, 113
serotonin
activity at and weight gain, 62
activity at, hypothermia and, 144
activity at, sexual dysfunction and, 104
blockade by clozapine, 4
records, of mental health patients vs. physical, 6
respiration, dyskinesia and, 123
respiratory rate, 141, 144. See also vital signs
restlessness, 39. See also akathisia
Extrapyramidal Symptom Rating Scale (ESRS), 43–50
retinopathy, pigmentary, 72
clozapine, 72
thioridazine, 72
rigidity, 39
Extrapyramidal Symptom Rating Scale (ESRS), 43–50
neuroleptic malignant syndrome, 59, 61
risk
cardiovascular, 141
diabetes mellitus, 24–9, 62
dyskinesia, tardive, 124, 125, 127
dyslipidemia, 62
factors
anticholinergic toxicity, 22
antipsychotic-induced extrapyramidal symptoms, 40
arythmias, 80, 81, 81, 85–7
blood dyscrasias, antipsychotic-induced, 13
cardiac arrhythmias, 142
cardiovascular disease, 31–3, 35, 37
cataracts, 69
diabetes mellitus, 29
dyskinesia, tardive, 123
for weight gain, 63
hepatic problems, 55
neuroleptic malignant syndrome, 59
schizophrenia as, 24
screening for, 175
seizures, 98, 100, 102
sexual dysfunction, 105
sudden cardiac death, 80, 81, 81, 85–7
thromboembolism, 135, 136
urinary incontinence, 129
weight gain as, 62, 63
hyperlipidemia, 32–3
hypertension, 62
metabolic syndrome, 5
See also under morbidity, mortality
seizure
antipsychotics, 100
sudden cardiac death, 141
thromboembolism, 137
risperidone, 4
agranulocytosis, 12, 13
akathisia, 42
anticholinergic effects, 20, 20
blood lipids, 32
cardiac death, sudden, 83
cardiovascular effects, 145
diabetes mellitus, 26
dyskinesia, tardive, 125
extrapyramidal symptoms, 40, 42
hepatic effects, 54
leukopenia, 13
micturition disturbances, 130
monitoring schedule, 167
neutropenia, 13
obesity and weight gain, 64
parkinsonism, 42
prolactin effects, 76
rabbit syndrome, 42
risk of morbidity, 5
sedation, 92
seizures, 99
sexual dysfunction, 106
sialorrhea, 114
skin reactions, 119
sleep disturbances, 92
thromboembolism, 137
urinary incontinence, 130
vital signs, 145
scales, monitoring, movement
disorders, 7
schizoaffective disorders
sexual dysfunction, 106, 107
urinary incontinence, 130
schizophrenia
cardiovascular disease, 31, 175
cataracts, 69, 70
diabetes mellitus in, 24, 25
dyskinesia, 123
epilepsy and, 98
heart rate variability, 142
life expectancy, 141
refractory, chlorpromazine and benztropine for, 42
risk of extrapyramidal symptoms and, 40
sexual dysfunction, 104, 106, 107
sleep disturbances, 89
second-generation antipsychotics, 91–3
thermoregulation, 143
thromboembolism, 135
urinary incontinence, 130
weight gain, 62
sialorrhea (cont.)
  muscarinic blockade and, 19
  olanzapine, 114
  paliperidone, 114
  quetiapine, 114
  risperidone, 114
  ziprasidone, 114
side effects, history, 3
  signs
  agranulocytosis, 14
  cardiac effects, 87
  dyskinesia, 125
  liver disease, 55
  neuroleptic malignant syndrome, 59–61
  thrombocytopenia, 14
  thromboembolism, 137
vital. See vital signs
Simpson Angus Scale, 7
skin reactions, 118–20, 119
  aripiprazole, 118
  chlorpromazine, 120
  clozapine, 118
  haloperidol, 120
  loxapine, 120
  monitoring, 120, 121
  olanzapine, 119
  paliperidone, 119
  quetiapine, 119
  risperidone, 119
  thioridazine, 120
  ziprasidone, 119
sleep
  chlorpromazine produces, 3
  sialorrhea and, 112
sleep disturbances, 89–95
  aripiprazole, 91
  clozapine, 91
  haloperidol, 93
  loxapine, 93
  monitoring, 94, 95
  olanzapine, 92
  paliperidone, 92
  perphenazine, 95
  quetiapine, 92
  risperidone, 92
  ziprasidone, 93
speech
  dyskinesia and, 123
  Extrapyramidal Symptom Rating Scale (ESRS), 44–50
  muscarinic blockade and, 19
  splenomegaly, liver disease, 55
  stools, pale, hepatic symptom, 55
  sudden cardiac death. See cardiac death
  sulpiride, sexual dysfunction, 107
  swallowing reflex, sialorrhea and, 112,
  113, 116
  sweating impairment, anticholinergic
effect, 18
  symptoms
  agranulocytosis, 14
  cardiac effects, 87
  dyskinesia, 125
  hepatic problems, 55
  neuroleptic malignant syndrome, 59–61
  thrombocytopenia, 14
  thromboembolism, 137
tachycardia, 141
  anticholinergic effect, 18
  anticholinergic effects, 141
  clozapine, 19
  quetiapine, 20
  muscarinic blockade and, 19, 141
temperature, 141. See also thermoregulation,
vital signs
thermoregulation, 143
  chlorpromazine, 143
  first-generation antipsychotics, 143
thioridazine
  anticholinergic effects, 20
  cardiac death, sudden, 84–5
  cataracts, 70
  monitoring schedule, 168
  obesity and weight gain, 66
  retinopathy, pigmentary, 72
  sedation, 93
  sexual dysfunction, 107
  skin reactions, 120
  urinary incontinence, 131
thiothixene
  cardiac death, sudden, 85
  leukotrycisis, 13
  leukopenia, 13
  monitoring schedule, 169
  neutropenia, 13
thioxanthenes
  risk of morbidity, 5
  sexual dysfunction, 107
thrombocytopenia, 12
aripiprazole, 12
clozapine, 12
definition, 14
olanzapine, 13
signs and symptoms, 14
ziprasidone, 13
thrombocytosis, clozapine, 12
thromboembolism, 135–9
clozapine, 136
monitoring, 138, 139
olanzapine, 136
paliperidone, 136
risk factors, 136
risperidone, 137
schizophrenia, 135
signs and symptoms, 137
ziprasidone, 137
tiredness, dopamine receptor blockade, 90
tolerability, extrapyramidal symptoms as measure of, 40
tolerance, 141, 142, 143
toxicity, anticholinergic, risk factors, 22
tremor, 39
Extrapyramidal Symptom Rating Scale (ESRS), 43–50
monitoring, 43
neuroleptic malignant syndrome, 59, 61
olanzapine, 41
trifluoperazine, monitoring schedule, 170
triglycerides, 31. See also dyslipidemia, hyperlipidemia, lipids
UKU scale, 7
urinary
incontinence. See under incontinence
tract disorders
anticholinergic effect, 18
muscarinic blockade and, 19
urine, dark
hepatic symptom, 55
vision
anticholinergic effects, 18
monitoring, 21
monitoring, 72
muscarinic blockade and, 19
vital signs, 141–7
aripiprazole, 144
chlorpromazine, 145
clinical inquiry, 145
clozapine, 144, 146
D_2 antagonists, 145
haloperidol, 147
monitoring, 146, 147
olanzapine, 144
paliperidone, 145
quetiapine, 145
risperidone, 145
ziprasidone, 145
vomiting, muscarinic blockade and, 19
weight gain, 62–3
risk for sleep apnea, 89
ziprasidone
akathisia, 42
anticholinergic effects, 22
blood lipids, 33
cardiac death, sudden, 84
diabetes mellitus, 26
dyskinesia, tardive, 125
extrapyramidal symptoms, 40, 42
hepatic effects, 55
leukopenia, 13
monitoring schedule, 171
neutropenia, 13
obesity and weight gain, 64
oculogyric crisis, 42
parkinsonism, 42
prolactin effects, 76
risk of morbidity, 5
sedation, 93
seizures, 100
sexual dysfunction, 107
sialorrhea, 114
skin reactions, 119
sleep disturbances, 93
thrombocytopenia, 13
thromboembolism, 137
urinary incontinence, 131
vital signs, 145
zuclopenthixol, monitoring schedule, 172